GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable ...
US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such ...
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S ...
Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Q. A renowned senior cardiologist in our area has been taking all his patients off statins and putting them on Repatha. He did this for my husband, and the results have been amazing. Within three ...
2don MSN
Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention
The VESALIUS-CV trial was a global, double-blind, randomized, placebo-controlled study that enrolled over 12,000 high-risk adults with known atherosclerotic cardiovascular disease/ASCVD or high-risk ...
Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...
US biotech Amgen (Nasdaq: AMGN) has reported that its cholesterol therapy Repatha (evolocumab) hit both primary endpoints in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback